Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 seropositivity and seroconversion in patients undergoing active cancer-directed therapy.
Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick ME, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A. Sun L, et al. Among authors: vonderheide rh. medRxiv [Preprint]. 2021 Jan 16:2021.01.15.21249810. doi: 10.1101/2021.01.15.21249810. medRxiv. 2021. PMID: 33469597 Free PMC article. Updated. Preprint.
Rates of COVID-19-related Outcomes in Cancer compared to non-Cancer Patients.
Sun L, Surya S, Le AN, Desai H, Doucette A, Gabriel P, Ritchie M, Rader D, Maillard I, Bange E, Huang A, Vonderheide RH, DeMichele A, Verma A, Mamtani R, Maxwell KN. Sun L, et al. Among authors: vonderheide rh. medRxiv [Preprint]. 2020 Aug 15:2020.08.14.20174961. doi: 10.1101/2020.08.14.20174961. medRxiv. 2020. PMID: 32817956 Free PMC article. Updated. Preprint.
Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients.
Sun L, Surya S, Le AN, Desai H, Doucette A, Gabriel P, Ritchie MD, Rader D, Maillard I, Bange E, Huang AC, Vonderheide RH, DeMichele A, Verma A, Mamtani R, Maxwell KN. Sun L, et al. Among authors: vonderheide rh. JNCI Cancer Spectr. 2021 Jan 21;5(1):Pkaa120. doi: 10.1093/jncics/pkaa120. eCollection 2021 Feb. JNCI Cancer Spectr. 2021. PMID: 33554040 Free PMC article.
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer.
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella L, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP; UPenn COVID Processing Unit; Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer N, DeMichele AM, Vardhana SA, Mamtani R, Huang AC. Bange EM, et al. Among authors: vonderheide rh. Res Sq [Preprint]. 2021 Feb 2:rs.3.rs-162289. doi: 10.21203/rs.3.rs-162289/v1. Res Sq. 2021. PMID: 33564756 Free PMC article. Updated. Preprint.
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA, Mamtani R, Huang AC. Bange EM, et al. Among authors: vonderheide rh. Nat Med. 2021 Jul;27(7):1280-1289. doi: 10.1038/s41591-021-01386-7. Epub 2021 May 20. Nat Med. 2021. PMID: 34017137 Free PMC article.
SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy.
Sun L, Surya S, Goodman NG, Le AN, Kelly G, Owoyemi O, Desai H, Zheng C, DeLuca S, Good ML, Hussain J, Jeffries SD, Kry YR, Kugler EM, Mansour M, Ndicu J, Osei-Akoto A, Prior T, Pundock SL, Varughese LA, Weaver J, Doucette A, Dudek S, Verma SS, Gouma S, Weirick ME, McAllister CM, Bange E, Gabriel P, Ritchie M, Rader DJ, Vonderheide RH, Schuchter LM, Verma A, Maillard I, Mamtani R, Hensley SE, Gross R, Wileyto EP, Huang AC, Maxwell KN, DeMichele A. Sun L, et al. Among authors: vonderheide rh. JCO Oncol Pract. 2021 Dec;17(12):e1879-e1886. doi: 10.1200/OP.21.00113. Epub 2021 Jun 16. JCO Oncol Pract. 2021. PMID: 34133219 Free PMC article.
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, Shea J, Gilmore J, Lledo L, Dengel K, Marshall A, Wherry EJ, Linette GP, Brennan A, Gonzalez V, Kulikovskaya I, Lacey SF, Plesa G, June CH, Vonderheide RH, Mitchell TC. Shah PD, et al. Among authors: vonderheide rh. Cancer Res Commun. 2023 May 9;3(5):821-829. doi: 10.1158/2767-9764.CRC-22-0486. eCollection 2023 May. Cancer Res Commun. 2023. PMID: 37377890 Free PMC article. Clinical Trial.
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.
Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH. Maity A, et al. Among authors: vonderheide rh. Br J Cancer. 2018 Nov;119(10):1200-1207. doi: 10.1038/s41416-018-0281-9. Epub 2018 Oct 15. Br J Cancer. 2018. PMID: 30318516 Free PMC article. Clinical Trial.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. Benci JL, et al. Among authors: vonderheide rh. Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022. Cell. 2016. PMID: 27912061 Free PMC article.
210 results